Lee Scott Golden - 02 Dec 2025 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Reporting relationship: Director
Issuer ticker: CVKD
Reported as of: 02 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Dec 2025, 20:08:16 UTC
Prior SEC filing: 03 Dec 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew K. Szot, Attorney-in-fact

Key filing fact

Lee Scott Golden filed Form 4 for Cadrenal Therapeutics, Inc. (CVKD) on 03 Dec 2025.

Key facts

This page summarizes Lee Scott Golden's Form 4 filing for Cadrenal Therapeutics, Inc. (CVKD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Dec 2025, 20:08.

Change

Previous filing in this sequence was filed on 03 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001686217 Primary reporting owner

Golden Lee Scott

Relationship: Director
Address: C/O CADRENAL THERAPEUTICS, INC.,, 822 A1A NORTH, SUITE 306, PONTE VEDRA
Signature: /s/ Matthew K. Szot, Attorney-in-fact
Signature date: 03 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CVKD transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +5,000
Change %
Price: $0.000000
Shares after: 5,000
Date: 02 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $8.27
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Consists of options to purchase 5,000 shares of common stock, which shall vest 1/3 on January 1, 2027 and thereafter pro rata on a monthly basis over 24 months, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant.